ENA Respiratory
Melbourne, Australia· Est.
Pan‑viral nasal spray prophylaxis using a TLR2/6 agonist to protect vulnerable patients from respiratory infections.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $22.4M
AI Company Overview
Pan‑viral nasal spray prophylaxis using a TLR2/6 agonist to protect vulnerable patients from respiratory infections.
Respiratory Infectious DiseasesImmunology
Technology Platform
Small‑molecule TLR2/6 agonist delivered as a nasal dry‑powder spray to activate innate mucosal immunity and accelerate viral clearance.
Opportunities
Broad‑spectrum, virus‑agnostic prophylaxis for at‑risk populations and pandemic preparedness could unlock multi‑billion‑dollar markets worldwide.
Risk Factors
Clinical efficacy across diverse viruses, regulatory approval for a prophylactic nasal spray, and competition from vaccines, monoclonal antibodies, and other intranasal antivirals.
Competitive Landscape
Few competitors offer a host‑defence‑enhancing nasal spray; ENA’s TLR2/6 agonist differentiates itself from vaccines and antivirals by providing rapid, broad protection without the need for pathogen‑specific formulation.